Androgen Deprivation

Positive Lymph Node Prostate Cancer Care Patterns Characterized

Positive Lymph Node Prostate Cancer Care Patterns Characterized

By

63% of patients were managed initially with observation.

Low-PSA, High-Grade Prostate Cancer Especially Lethal

Low-PSA, High-Grade Prostate Cancer Especially Lethal

By

Men with PSA values of 2.5 ng/mL or less and Gleason 8 to 10 prostate tumors are at higher risk of death than other high-risk PCa patients.

Abiraterone Plus ADT Ups Prostate Cancer Patient Survival

Abiraterone Plus ADT Ups Prostate Cancer Patient Survival

By

The 3-year overall survival rate among prostate cancer patients starting long-term hormone therapy was 83% vs 76% for men receiving abiraterone plus ADT vs ADT alone.

Prostate Cancer Subtypes Differ in ADT Response After Surgery

Prostate Cancer Subtypes Differ in ADT Response After Surgery

Only luminal B prostate cancers were significantly associated with postoperative response to ADT in a subset analysis in retrospective cohorts.

PCa Salvage Radiation Plus Anti-Androgen Therapy Improves Outcomes

PCa Salvage Radiation Plus Anti-Androgen Therapy Improves Outcomes

By

Combined treatment for recurrent prostate cancer after radical prostatectomy results in decreased long-term all-cause and cancer-specific mortality.

Androgen Suppression May Prevent Intravesical Recurrence of NMIBC

Androgen Suppression May Prevent Intravesical Recurrence of NMIBC

During a median followup of 3.6 and 3.0 years intravesical recurrence developed in 4 (12.5%) and 59 men (30.1%) with and without androgen suppression therapy, respectively.

ADT Not Linked to Dementia in Nonmetastatic Prostate Cancer

ADT Not Linked to Dementia in Nonmetastatic Prostate Cancer

No increased risk of dementia for androgen deprivation therapy use versus nonuse.

Exercise Training Improves Quality of Life for PCa Patients

Exercise Training Improves Quality of Life for PCa Patients

By

Patient motivation is pivotal to the success of exercise interventions, researchers noted.

Dementia Linked to Prostate Cancer ADT

Dementia Linked to Prostate Cancer ADT

By

The risk of dementia was 2-fold higher among ADT users.

Adding Zoledronic Acid to ADT Does Not Delay PCa Treatment Failure

Adding Zoledronic Acid to ADT Does Not Delay PCa Treatment Failure

By

Study tested the combination in men with treatment-naïve prostate cancer and bone metastasis.

Long-term ADT Use Not Linked With Cognitive Decline

Long-term ADT Use Not Linked With Cognitive Decline

By

Ongoing use of androgen-deprivation therapy (ADT) for up to 36 months is not associated with cognitive decline among men with prostate cancer.

Genetic Variant in Prostate Cancer Patients May Predict ADT Failure

Genetic Variant in Prostate Cancer Patients May Predict ADT Failure

By

Men with 1 or 2 copies of the HSD3B1 (1245C) allele are more likely to experience disease progression.

Radical Local Therapy Offers Mortality Benefit in Very High-Risk PCa

Radical Local Therapy Offers Mortality Benefit in Very High-Risk PCa

By

Prostatectomy and radiotherapy with or without ADT reduced prostate cancer-specific and all-cause mortality rates.

Adjuvant ADT May Up Mortality in Black Prostate Cancer Patients

Adjuvant ADT May Up Mortality in Black Prostate Cancer Patients

By

Androgen deprivation increased all-cause mortality risk by 77% among black men who underwent brachytherapy for favorable-risk prostate cancer.

ADT Plus Radiation Improves Survival in Metastatic Prostate Cancer

ADT Plus Radiation Improves Survival in Metastatic Prostate Cancer

Superior median, 5-year OS for prostate RT plus ADT versus ADT alone in propensity score analyses.

Cardiac Event Risk in PCa Patients Higher After Radiation Than Surgery

Cardiac Event Risk in PCa Patients Higher After Radiation Than Surgery

By

Radiation therapy also is associated with a greater likelihood of fractures.

Androgen Suppression With Salvage Radiotherapy May Fight Progression

Androgen Suppression With Salvage Radiotherapy May Fight Progression

Adding short-term androgen suppression to salvage radiotherapy may benefit men with prostate cancer who have undergone radical prostatectomy.

Low-Carb Diet May Curb Adverse Effects of Prostate Cancer ADT

Low-Carb Diet May Curb Adverse Effects of Prostate Cancer ADT

By

New findings show metabolic changes suggesting that a carbohydrate-restricted diet may improve insulin sensitivity.

ADT for Prostate Cancer Linked to Depression

ADT for Prostate Cancer Linked to Depression

Researchers find 23% increased risk compared to men who received other treatments.

Bevacizumab Plus ADT May Up Survival in Recurrent Prostate Cancer

Bevacizumab Plus ADT May Up Survival in Recurrent Prostate Cancer

Adding bevacizumab to androgen deprivation therapy (ADT) resulted in improved relapse-free survival in patients with hormone-sensitive prostate cancer.

Steps for Reducing CVD Risks in Prostate Cancer Patients

Steps for Reducing CVD Risks in Prostate Cancer Patients

By

The advice is useful as clinicians wait for formal guidelines.

Modest Survival Benefit with EBRT + Brachytherapy in Intermediate PCa

Modest Survival Benefit with EBRT + Brachytherapy in Intermediate PCa

By

Combined radiotherapy remains controversial due to the increased potential for toxicities.

Adjuvant Bicalutamide With Salvage RT Improves Local PCa Survival

Adjuvant Bicalutamide With Salvage RT Improves Local PCa Survival

Anti-androgen therapy during and after salvage radiotherapy in patients with localized prostate cancer significantly improved long-term overall survival.

Study: ADT, Radiotherapy Possibly Reduce Bladder Cancer Risk

Study: ADT, Radiotherapy Possibly Reduce Bladder Cancer Risk

By

The finding of lower bladder cancer incidence in patients receiving pelvic radiation contrasts with previous research.

Bipolar Androgen Therapy Promising for Advanced Hormone-Sensitive PCa

Bipolar Androgen Therapy Promising for Advanced Hormone-Sensitive PCa

By

In a small study, high-dose testosterone given intermittently with androgen deprivation therapy lowered PSA levels without serious adverse effects.

Gene Signature May Predict PCa Hormone Treatment Failure

Gene Signature May Predict PCa Hormone Treatment Failure

By

A 12-gene androgen deprivation therapy resistance signature may help guide therapeutic decision making after radical prostatectomy.

Adverse Effects Greater for Medical vs. Surgical Castration in PCa

Adverse Effects Greater for Medical vs. Surgical Castration in PCa

Higher risks of several clinically relevant adverse effects compared with surgical castration.

Low Testosterone Before ADT Predicts Poor Prognosis in Metastatic PCa

Low Testosterone Before ADT Predicts Poor Prognosis in Metastatic PCa

By

The study found no association with obesity, however, unlike previous studies.

Androgen Deprivation Therapy Linked to Alzheimer's Disease

Androgen Deprivation Therapy Linked to Alzheimer's Disease

A new study by University of Pennsylvania and Stanford researchers highlights a possible link between men who receive androgen deprivation therapy (ADT) and the future onset of Alzheimer's disease.

Prostate Cancer ADT May Increase Thromboembolic Disease Risk

Prostate Cancer ADT May Increase Thromboembolic Disease Risk

By

The risk is highest among patients who switch from anti-androgen to GnRH agonist therapy.

Sign Up for Free e-newsletters